STRATLINKS is your outsourced regional commercial office — we plan your market entry, select and govern your distributors, and represent your interests across 20 focus markets, so you can grow here without building permanent regional infrastructure.
STRATLINKS is a Dubai-headquartered Regional Commercial Management Organization (RCMO) built for global medical device manufacturers entering or scaling across Emerging Markets. We are not a distributor and we do not take title to product.
We are the team that plans your market entry, selects and governs your distributors, and represents your interests across the region — so you can grow here without building permanent regional infrastructure.
"Our incentives sit entirely on your side of the table — shaped by your outcomes, never by channel margin."
Manufacturers entering Emerging Markets typically face the same set of problems — STRATLINKS exists to solve exactly this, bringing the regional commercial discipline of an in-house office, without the fixed cost, hiring risk or multi-year commitment.
Appointed by chance rather than strategy, with inconsistent performance and no shared KPIs.
No regional demand visibility to support production and supply chain planning.
20-plus markets, 20-plus regimes — no local hire can navigate all of them alone.
No one empowered to represent you — the result is lost revenue and weak tender participation.
Our service portfolio spans first market entry to long-term regional governance.
Country prioritization, opportunity sizing and go-to-market planning tailored to your product category.
Identification, vetting and appointment of distributors that meet your standards — not just the first available option.
Ongoing oversight, KPI scorecards and quarterly business reviews that keep your channel accountable.
Sales training, CRM optimization and capability-building delivered directly to your distributor teams.
Competitive tracking, pricing benchmarks and regulatory monitoring across all priority markets.
End-to-end commercialization planning for new product introductions.
A fractional Regional VP/GM who represents you with customers, KOLs and at regional congresses.
Coordination with in-market regulatory and market-access specialists across SFDA, MOHAP, NHRA and other authorities.
Every STRATLINKS engagement follows the same proprietary delivery framework, from first conversation to regional scale.
Understand your product, ambitions and constraints.
Design a market-specific strategy.
Identify and appoint the right partners.
Stand up governance and reporting.
Drive commercial execution.
Continuously improve performance.
Expand coverage market by market.
The Emerging Markets we serve are among the few medtech markets combining above-average growth with structural underinvestment in commercial infrastructure.
Sources: Fortune Business Insights, MarketDataForecast, BioNixus GCC Medical Devices Report, MarkNtel Advisors (2025–2026 publications). Figures vary by methodology and are presented as directional ranges.
Saudi Vision 2030, the UAE Digital Health Strategy and Qatar's National Health Strategy are expanding hospital capacity and tightening procurement standards.
Rising cardiovascular disease, diabetes and orthopedic conditions are expanding demand across monitoring, diagnostic and implantable categories.
SFDA, MOHAP/DHA/DOH, NHRA and MOPH each run distinct registration pathways across the region.
Roughly 400 GCC healthcare transactions in under four years signal active private equity and strategic interest.
Seven profiles, each with a distinct pain point and a natural first service.
| Segment | Profile & pain point | Primary entry service |
|---|---|---|
| European SMEs | Strong, CE-marked product with no MEA commercial footprint; too small to justify a regional office, but need credible in-market representation fast. | Market Entry Strategy + Distributor Search |
| US & venture-backed innovators | FDA-cleared and capital-efficient by mandate; the board wants regional revenue proof points without regional headcount. | Market Entry Assessment + Fractional Regional VP |
| Japanese & Korean manufacturers | Technically excellent, methodical and relationship-driven; need a trusted intermediary who operates to their governance standards. | Distributor Governance + Commercial Excellence |
| Premium Asian manufacturers | Increasingly capable product, but a regional credibility gap; need third-party governance to reassure hospital buyers. | Distributor Governance + Market Intelligence |
| Private equity portfolio companies | The sponsor wants regional growth proof for the next raise or exit within a defined hold period — capex for a regional office is off the table. | Market Entry Strategy + Executive Representation |
| Manufacturers with legacy distributors | An existing network that's underperforming, opaque or misaligned, with no local visibility to fix it directly. | Distributor Governance & Turnaround |
| Digital health & connected devices | The fastest-growing sub-segment (~18% CAGR); asset-light teams with no experience in physical distribution or tenders. | Market Entry Strategy + Distributor Search |
Our incentives sit entirely on your side of the table — shaped by your outcomes, never by channel margin.
One partner covering Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, Oman, Egypt, Jordan, Iraq, Lebanon and North Africa.
Our team, methodology and technology platform are purpose-built for medical device commercialization — not adapted from pharma or generic consulting.
A fraction of the cost of an in-house regional office, operational within weeks rather than the months a direct hire requires.
| Alternative | What it offers | Where STRATLINKS wins |
|---|---|---|
| In-house regional office | Full control, dedicated headcount | A fraction of the fixed cost; operational from month one; no hiring or visa risk |
| Distributor / commercial agent | Immediate market access, local relationships | No channel conflict; you retain commercial control and IP over the relationship |
| Global management consultancy | Strategic credibility, brand recognition | Ongoing accountability and execution, not a report; regional MedTech specialization |
| Generalist CSO (pharma-oriented) | Field rep deployment, sales infrastructure | Purpose-built for MedTech distributor governance, not headcount deployment |
A market entry assessment, a distributor search, or launch planning for a single country.
Ongoing governance, reporting and representation across one or several markets, scaled to your footprint.
Fractional executive representation for manufacturers who need seniority in-market without a full-time regional hire.
Every engagement begins with a scoping conversation to understand your product, current regional footprint and growth ambitions. We recommend the model that fits — not the model that maximizes our fee.
We'd welcome a conversation about your specific market and product category.